Patents by Inventor Bertrand Le Bourdonnec

Bertrand Le Bourdonnec has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PURINES AND METHODS OF THEIR USE
    Publication number: 20240150358
    Abstract: Disclosed are compounds useful in the treatment of neurological disorders. The compounds described herein, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological diseases.
    Type: Application
    Filed: June 3, 2021
    Publication date: May 9, 2024
    Inventors: Kerem OZBOYA, Iwona WRONA, Bertrand LE BOURDONNEC, Matthew LUCAS, Vanessa KURIA, Madeline MACDONNELL, Byron DELABARRE
  • ULK INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20240150368
    Abstract: Described herein are compounds that are inhibitors of autophagy and their use in the treatment of disorders such as cancers.
    Type: Application
    Filed: August 28, 2023
    Publication date: May 9, 2024
    Inventors: Justin T. Proto, Andrew Michael Harned, Kristen Stoltz, Timothy Caldwell, Lakshminarayana Vogeti, Yu Mi Ahn, Bertrand Le Bourdonnec, Daniel L. Flynn
  • Compounds and uses thereof
    Patent number: 11970486
    Abstract: The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: April 30, 2024
    Assignee: Janssen Pharmaceutica NV
    Inventors: Bertrand Le Bourdonnec, Matthew Lucas, Kerem Ozboya, Bhaumik Pandya, Parcharee Tivitmahaisoon, Iwona Wrona
  • COMPOUNDS AND USES THEREOF
    Publication number: 20240124435
    Abstract: The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.
    Type: Application
    Filed: September 27, 2023
    Publication date: April 18, 2024
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Matthew Lucas, Bertrand Le Bourdonnec, Iwona Wrona, Bhaumik Pandya, Parcharee Tivitmahaisoon, Kerem Ozboya, Benjamin Vincent, Daniel Tardiff, Jeff Piotrowski, Eric Solis, Robert Scannevin, Chee-Yeun Chung, Rebecca Aron, Kenneth Rhodes
  • GCN2 and perk kinase inhibitors and methods of use thereof
    Patent number: 11912668
    Abstract: Described herein are compounds, such as compounds represented by Formula I-R: and pharmaceutically acceptable salts, enantiomers, stereoisomers, and tautomers thereof, that are inhibitors of GCN2 kinase or PERK kinase, and methods of treating diseases, including diseases associated with GCN2 kinase or PERK kinase, with said compounds.
    Type: Grant
    Filed: November 17, 2021
    Date of Patent: February 27, 2024
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Daniel L. Flynn, Patrick Kearney, Jeffery Zwicker, Gada Al-Ani, Salim Javed, Yu Mi Ahn, Kristen Stoltz, Bertrand Le Bourdonnec
  • Compounds and uses thereof
    Patent number: 11873298
    Abstract: The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.
    Type: Grant
    Filed: October 24, 2018
    Date of Patent: January 16, 2024
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Matthew Lucas, Bertrand Le Bourdonnec, Iwona Wrona, Bhaumik Pandya, Parcharee Tivitmahaisoon, Kerem Ozboya, Benjamin Vincent, Daniel Tardiff, Jeff Piotrowski, Eric Solis, Robert Scannevin, Chee-Yeun Chung, Rebecca Aron, Kenneth Rhodes
  • RAF KINASE INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20230357179
    Abstract: Described herein are compounds that are RAF inhibitors and their use in the treatment of disorders such as cancers.
    Type: Application
    Filed: December 9, 2022
    Publication date: November 9, 2023
    Inventors: Daniel L. Flynn, Yu Mi Ahn, Lakshminarayana Vogeti, Bertrand Le Bourdonnec
  • AMINO ALCOHOL COMPOUNDS AND USES THEREOF
    Publication number: 20230339890
    Abstract: The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.
    Type: Application
    Filed: June 3, 2021
    Publication date: October 26, 2023
    Inventors: Iwona WRONA, Kerem OZBOYA, Bertrand LE BOURDONNEC, Vanessa KURIA, Madeline MACDONNELL, Matthew LUCAS, Byron DELABARRE
  • BICYCLIC HETEROARENES AND METHODS OF THEIR USE
    Publication number: 20230271965
    Abstract: Disclosed are compounds useful in the treatment of neurological disorders. The compounds described herein, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological diseases.
    Type: Application
    Filed: June 3, 2021
    Publication date: August 31, 2023
    Inventors: Kerem OZBOYA, Iwona WRONA, Bertrand LE BOURDONNEC, Matthew LUCAS, Vanessa KURIA, Madeline MACDONNELL, Byron DELABARRE
  • RAF KINASE INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20230257352
    Abstract: Described herein are compounds that are RAF inhibitors and their use in the treatment of disorders such as cancers.
    Type: Application
    Filed: December 9, 2022
    Publication date: August 17, 2023
    Inventors: Daniel L. Flynn, Yu Mi Ahn, Lakshminarayana Vogeti, Bertrand Le Bourdonnec
  • COMPOUNDS AND USES THEREOF
    Publication number: 20230116101
    Abstract: The present invention features compounds useful in the treatment of neurological disorders and primary brain cancer. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders and primary brain cancer.
    Type: Application
    Filed: November 13, 2020
    Publication date: April 13, 2023
    Inventors: Iwona WRONA, Kerem OZBOYA, Matthew LUCAS, Bhaumik PANDYA, Bertrand LE BOURDONNEC
  • COMPOUNDS AND USES THEREOF
    Publication number: 20230078764
    Abstract: The present invention features compounds useful in the treatment of neurological disorders and primary brain cancer. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders and primary brain cancer.
    Type: Application
    Filed: March 20, 2020
    Publication date: March 16, 2023
    Inventors: Bertrand LE BOURDONNEC, Matthew LUCAS, Kerem OZBOYA, Bhaumik PANDYA, Daniel TARDIFF, Parcharee TIVITMAHAISOON, Iwona WRONA
  • COMPOUNDS AND USES THEREOF
    Publication number: 20220298168
    Abstract: The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.
    Type: Application
    Filed: September 22, 2020
    Publication date: September 22, 2022
    Inventors: Bertrand LE BOURDONNEC, Matthew LUCAS, Kerem OZBOYA, Bhaumik PANDYA, Daniel TARDIFF, Parcharee TIVITMAHAISOON, Iwona WRONA
  • COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS
    Publication number: 20220110920
    Abstract: The invention provides compositions and methods for treating neurological disorders, such as amyotrophic lateral sclerosis, frontotemporal degeneration, and Alzheimer's disease, among others. Using the compositions and methods described herein, a patient having a neurological disorder, such as a neurological disorder associated with TAR-DNA binding protein (TDP)-43 aggregation, may be administered an inhibitor of cytochrome P450 (CYP450) isoform 51A1 (CYP51A1), also referred to herein as lanosterol 14-alpha demethylase, so as to treat an underlying etiology of the disorder and/or to alleviate one or more symptoms of the disease. The inhibitor of CYP51A1 may be a small molecule, anti-CYP51A1 antibody or antigen-binding fragment thereof, or a compound, such as an interfering RNA molecule, that attenuates CYP51A1 expression.
    Type: Application
    Filed: December 23, 2021
    Publication date: April 14, 2022
    Inventors: Rebecca ARON, Bhaumik PANDYA, Daniel TARDIFF, Jeff PIOTROWSKI, Matthew LUCAS, Bertrand LE BOURDONNEC, Kenneth RHODES, Robert SCANNEVIN
  • METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
    Publication number: 20220040167
    Abstract: The present disclosure provides compounds and methods useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.
    Type: Application
    Filed: April 9, 2021
    Publication date: February 10, 2022
    Inventors: Benjamin Matteson VINCENT, Daniel Forrest TARDIFF, Jeff Scott PIOTROWSKI, Eric SOLIS, Robert Hughie SCANNEVIN, Chee-Yeun CHUNG, Rebecca ARON, Bertrand LE BOURDONNEC, Matthew LUCAS, Kenneth RHODES
  • Compositions and methods for the treatment and prevention of neurological disorders
    Patent number: 11241417
    Abstract: The invention provides compositions and methods for treating neurological disorders, such as amyotrophic lateral sclerosis, frontotemporal degeneration, and Alzheimer's disease, among others. Using the compositions and methods described herein, a patient having a neurological disorder, such as a neurological disorder associated with TAR-DNA binding protein (TDP)-43 aggregation, may be administered an inhibitor of cytochrome P450 (CYP450) isoform 51A1 (CYP51A1), also referred to herein as lanosterol 14-alpha demethylase, so as to treat an underlying etiology of the disorder and/or to alleviate one or more symptoms of the disease. The inhibitor of CYP51A1 may be a small molecule, anti-CYP51A1 antibody or antigen-binding fragment thereof, or a compound, such as an interfering RNA molecule, that attenuates CYP51A1 expression.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: February 8, 2022
    Assignee: Yumanity Therapeutics, Inc.
    Inventors: Rebecca Aron, Bhaumik Pandya, Daniel Tardiff, Jeff Piotrowski, Matthew Lucas, Bertrand Le Bourdonnec, Kenneth Rhodes, Robert Scannevin
  • COMPOUNDS AND USES THEREOF
    Publication number: 20210139471
    Abstract: The present invention features compounds useful in the treatment of neurological disorders and primary brain cancer. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders and primary brain cancer.
    Type: Application
    Filed: January 24, 2020
    Publication date: May 13, 2021
    Inventors: Iwona WRONA, Kerem OZBOYA, Matthew LUCAS, Bhaumik PANDYA, Bertrand LE BOURDONNEC
  • Methods for the treatment of neurological disorders
    Patent number: 10973810
    Abstract: The present disclosure provides compounds and methods useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: April 13, 2021
    Assignee: Yumanity Therapeutics, Inc.
    Inventors: Benjamin Vincent, Daniel Tardiff, Jeff Piotrowski, Eric Solis, Robert Scannevin, Chee-Yeun Chung, Rebecca Aron, Bertrand Le Bourdonnec, Matthew Lucas, Kenneth Rhodes
  • Compounds and uses thereof
    Patent number: 10919885
    Abstract: The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: February 16, 2021
    Assignee: Yumanity Therapeutics, Inc.
    Inventors: Iwona Wrona, Parcharee Tivitmahaisoon, Daniel Tardiff, Bhaumik Pandya, Kerem Ozboya, Matthew Lucas, Bertrand Le Bourdonnec
  • COMPOUNDS AND USES THEREOF
    Publication number: 20200262828
    Abstract: The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.
    Type: Application
    Filed: October 24, 2018
    Publication date: August 20, 2020
    Inventors: Matthew LUCAS, Bertrand LE BOURDONNEC, Iwona WRONA, Bhaumik PANDYA, Parcharee TIVITMAHAISOON, Kerem OZBOYA, Benjamin VINCENT, Daniel TARDIFF, Jeff PIOTROWSKI, Eric SOLIS, Robert SCANNEVIN, Chee-Yeun CHUNG, Rebecca ARON, Kenneth RHODES